United States

AEterna Zentaris Inc (AEZS.O)

AEZS.O on Consolidated Issue listed on NASDAQ Capital Market

29 Sep 2016
Change (% chg)

$-0.03 (-0.87%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for AEZS.O


Aeterna Zentaris Inc. is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women's health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others. The... (more)


Beta: 1.85
Market Cap(Mil.): $33.98
Shares Outstanding(Mil.): 9.94
Dividend: --
Yield (%): --


  AEZS.O Industry Sector
P/E (TTM): -- 44.84 37.54
EPS (TTM): -9.24 -- --
ROI: -86.77 -0.27 13.98
ROE: -391.46 -2.93 14.88

BRIEF-AEterna Zentaris announces expiration of remaining Series B warrants

* AEterna Zentaris announces expiration of remaining Series B warrants

Sep 14 2016

BRIEF-Aeterna Zentaris reports Q2 loss per share $0.71

* Aeterna Zentaris reports second quarter 2016 financial and operating results

Aug 09 2016

BRIEF-Aeterna and Rafa Laboratories sign license agreement for Zoptrex in Israel

* Aeterna Zentaris and Rafa Laboratories sign exclusive license agreement for Zoptrex in Israel

Aug 01 2016

BRIEF-Aeterna Zentaris, Orient Europharma sign license agreement for Zoptrex

* Aeterna Zentaris and Orient Europharma Co Ltd sign exclusive license agreement for Zoptrex in Taiwan and Southeast Asia

Jul 01 2016

BRIEF-Aeterna zentaris to file a NDA for zoptrex in first half of 2017

* Aeterna Zentaris reconfirms commitment to LHRH-receptor targeting zoptrex during 2016 ASCO annual meeting

Jun 06 2016

BRIEF-Aeterna Zentaris acquires U.S. Promotional rights for prostate cancer blood test

* Aeterna zentaris acquires exclusive u.s. Promotional rights for apifiny prostate cancer blood test Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

Apr 27 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Thomson Reuters Stock Report
Provider : ValuEngine, Inc.
Provider : S&P Capital IQ Quantitative Report
Provider : Reuters Investment Profile
Provider : Pechala's Reports

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.